She Dismissed Her Mouth Sore as Stress. At 23, She Lost Her Tongue.
Why visual examination alone isn’t enough to catch oral cancer early
THE DATA YOUR PATIENTS NEED TO KNOW:
• 1 in 5 oral cancer cases occur in patients under age 55
• Young adult oral cancer (under 44) incidence is rising, particularly among women
• Stage 1 detection: 80-85% five-year survival rate
• Stage 4 detection: only 20-30% five-year survival rate
• The difference between early and late detection: more than 60 percentage points in survival
A ROUTINE EXAM COULD HAVE CHANGED EVERYTHING
Jessica Tappenden-Rowell was exactly the kind of patient who slips through the cracks. At 23, healthy, non-smoker, no family history, she dismissed a small lesion under her tongue as a stress ulcer. It looked like dozens of benign lesions you see every week.
But it wasn’t.
“It just started getting weirder, there was redness and there were white bumps around it,” Jessica explained. “I could see that it was getting worse. It didn’t even cross my mind that it would be something bad.”
By the time she sought care, what appeared to be a simple ulcer had progressed to squamous cell carcinoma requiring complete tongue removal and reconstruction using a forearm skin graft. Months of speech therapy followed. Permanent eating difficulties remain.
Her surgeon confirmed what research shows: “Even if you had been a severe alcoholic and smoker, at your age this would not have done anything to you yet.” The cause in young patients like Jessica often remains unexplained.
The question isn’t why she got cancer. The question is: could earlier detection have saved her tongue?
THE CLINICAL CHALLENGE: EARLY LESIONS LOOK BENIGN
Jessica’s case illustrates the fundamental problem with visual-only oral cancer screening:
Early-stage dysplastic changes and malignancies often appear identical to common benign conditions under white light examination. The tissue changes that signal cancer’s earliest stages frequently occur beneath the visible surface, where they’re invisible to the naked eye but detectable with tissue fluorescence visualization.
Recent epidemiological data reveals a shifting demographic that challenges traditional risk-based screening:
• Approximately 20% of oral and oropharyngeal cancers now occur in patients under 55
• Young adult oral cancer is the only head and neck cancer subset showing significant proportional increase
• Many young patients present with no traditional risk factors
• Early lesions in young patients are particularly likely to be dismissed as benign
This means age-based and risk-based screening protocols miss an increasing number of cases at their most treatable stages.
WHAT THE SURVIVAL DATA TELLS US
The difference between catching oral cancer at Stage 1 versus Stage 4 is stark:
Stage 1: 80-85% five-year survival, often requiring only minor excision with minimal functional impact
Stage 4: 20-30% five-year survival, typically requiring extensive surgery like glossectomy with permanent quality-of-life impacts
Research published in the Journal of Oncology demonstrates that routine dental visits provide the most frequent opportunities for early detection. Regular dental care correlates with improved survival, while infrequent care correlates with advanced-stage diagnosis.
Your practice sits at the frontline of early detection. The question is whether your screening protocol can identify suspicious changes before they progress to Jessica’s outcome.
BEYOND VISUAL EXAMINATION: TISSUE FLUORESCENCE VISUALIZATION
VELscope addresses the fundamental limitation of white light examination: the inability to reliably identify dysplastic tissue changes in their earliest stages.
The tissue fluorescence visualization system enables you to:
• Visualize abnormal tissue changes not visible under standard examination
• Identify dysplastic changes before they progress to invasive carcinoma
• Provide immediate visual feedback during routine patient visits
• Document baseline patterns for longitudinal monitoring
• Increase early detection rates across all patient demographics
This isn’t about replacing clinical judgment or histopathological diagnosis. VELscope serves as an adjunctive screening tool that enhances your existing protocols, helping identify lesions that warrant biopsy or closer monitoring before they progress to stages requiring devastating interventions.
THE PRACTICE IMPACT: PREVENTION VS. INTERVENTION
Compare two patient journeys:
Without Enhanced Screening:
• Early lesion appears benign under white light
• No intervention recommended
• Patient returns when symptoms worsen
• Biopsy confirms advanced malignancy
• Referral for major surgical intervention
• Permanent functional impairment
With VELscope Screening:
• Tissue fluorescence reveals abnormal patterns
• Immediate referral for biopsy
• Diagnosis at earliest stage
• Minor excision preserves function
• Patient outcome: cancer-free with normal quality of life
For your practice, implementing adjunctive screening represents:
• Enhanced standard of care with improved patient outcomes
• Advanced diagnostic capabilities that differentiate your practice
• Systematic protocols for identifying and documenting suspicious lesions
• Patient education tool demonstrating proactive preventive care
• Billable screening procedures integrated into comprehensive exams
• Risk management through enhanced detection and documentation
JESSICA’S MESSAGE TO DENTAL PROFESSIONALS
Jessica’s story ends with a clear message: “If you have an ulcer that has not gone away within two weeks, get it checked. The earlier you go, the less chance of this type of surgery. If I had gone earlier, I might not have needed such a large portion of my tongue removed.”
Her surgeon acknowledged what the statistics confirm: earlier detection would likely have meant preserving most or all of her tongue.
Today, she struggles with speech when tired. Eating remains challenging. Chocolate sticks to the roof of her mouth. She can’t feel or taste on one side. “I still have some days where I struggle a bit,” she explains.
While she’s cancer-free, the permanent impact on her quality of life is profound.
The question for your practice: how many patients like Jessica are you seeing whose early lesions appear benign but aren’t?
MAKE ENHANCED SCREENING YOUR STANDARD OF CARE
Every patient deserves screening that goes beyond visual examination alone.
VELscope technology gives you the ability to identify tissue changes in their earliest stages, providing your patients the critical advantage of detection before cancer progresses to stages requiring life-altering interventions.
The tissue fluorescence visualization system integrates seamlessly into your existing exam protocols, taking just minutes to perform while significantly enhancing your diagnostic capabilities.
Ready to enhance your practice’s screening capabilities?
Contact us today to:
• Schedule a demonstration of VELscope technology
• Discuss integration into your practice protocols
• Learn about financing options and implementation support
• See how enhanced screening can become your standard of care
Call 1-888-658-5231
Visit: velscopeshop.com/contact
Give your patients the advantage of early detection. Give yourself the confidence that comes from enhanced screening capabilities.
—
References:
American Cancer Society. Cancer Facts & Figures 2026. Oral Cavity and Oropharyngeal Cancer Key Statistics.
Lenoci D, et al. (2024). Oral cancer in young adults: incidence, risk factors, prognosis, and molecular biomarkers. Frontiers in Oncology.
National Cancer Institute SEER Program. Cancer Stat Facts: Oral Cavity and Pharynx Cancer.
NIDCR. Oral Cancer 5-Year Survival Rates by Race, Sex, and Stage of Diagnosis.
Help support the fight against oral cancer by supporting Saving Face.
Looking to add oral mucosal screening to your practice? The next-generation VELscope Mantis is now available factory-direct — explore pricing, the bundle, and what’s included.